Sensus Healthcare (NASDAQ:SRTS) Announces Earnings Results, Beats Estimates By $0.06 EPS

Sensus Healthcare (NASDAQ:SRTS) released its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06, Zacks reports. The firm had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $6.31 million. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.

Sensus Healthcare Price Performance

NASDAQ:SRTS traded up $0.68 during trading hours on Friday, reaching $4.20. 264,443 shares of the company traded hands, compared to its average volume of 168,941. The firm’s 50-day moving average is $3.28 and its 200-day moving average is $4.08. The stock has a market cap of $69.05 million, a P/E ratio of -70.00 and a beta of 1.38. Sensus Healthcare has a 1-year low of $3.03 and a 1-year high of $9.33.

Institutional Trading of Sensus Healthcare

A hedge fund recently raised its stake in Sensus Healthcare stock. Geode Capital Management LLC lifted its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 2.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 153,917 shares of the company’s stock after purchasing an additional 3,766 shares during the quarter. Geode Capital Management LLC owned about 0.94% of Sensus Healthcare worth $730,000 as of its most recent SEC filing. 25.30% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Lake Street Capital cut their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 8th. Wall Street Zen raised shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Finally, HC Wainwright dropped their price objective on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sensus Healthcare presently has an average rating of “Hold” and a consensus target price of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.